Investigating a Vaccine Against Plague (PlaVac)

This study is no longer recruiting

You are invited to take part in a research study to test a vaccine against Plague. This study is being conducted by the Oxford Vaccine Group, part of the University of Oxford, and is funded by Innovate UK. 

If you are aged 18 to 55 years old and in good health, then you may be eligible to take part in the study. We will provide reimbursement up to £630 for your time, inconvenience and travel. The total study participation time is up to 1 year. 

COVID-19 Vaccine Study COV001

What is the purpose of this trial?

The purpose of this study is to test a new vaccine against COVID-19 in healthy volunteers.

A new virus causing respiratory disease emerged in Wuhan, China in December 2019 and has since rapidly spread to many other countries around the world, despite unprecedented containment efforts. The virus is part of the Coronavirus family which may cause respiratory infections ranging from the common cold to more severe diseases. This recently discovered coronavirus causes coronavirus disease COVID-19.

Understanding RSV: Severe disease and the long term consequences

Understanding RSV: Severe disease and the long term consequences

Oxford Vaccine Group are inviting volunteers to take part in a study to help us learn more about the virus that most commonly causes coughs, colds and chest infections in young children, and sometimes causes children to be so unwell they have to be admitted to hospital.

Some facts about RSV disease (respiratory syncytial virus):

Be on the TEAM: Teenagers against Meningitis

The Oxford Vaccine Group are inviting students in school year 12 to take part in a research project to understand whether immunising teenagers with vaccines against ‘Meningitis B’ could protect them and the rest of the community against these potentially deadly bacteria. This is a national study involving 24 000 year 12 students across the United Kingdom.  Teenagers at participating schools are being asked to take part by local research teams involved.

Burden of RSV Disease

Some facts about RSV disease (respiratory syncytial virus):

RSV is a virus;

  • it causes coughs, colds and chest infections
  • is responsible for around 1 in 6 hospital admissions for infants  in the UK
  • The second largest worldwide cause of deaths in children between one month and 1 year of age, most are in Asia and Africa

What do we want to do?

We would like to identify 2000 babies from birth and follow them up to see if any become unwell with RSV disease

Ebola Vaccine Registry Study

THIS STUDY IS NOW IN FOLLOW UP

What is the purpose of this study?

Eligible participants for this study have previously received an experimental Ebola vaccine- Ad26.ZEBOV and MVA-BN-Filo. The purpose of this study is to collect long-term safety data from these participants who received two experimental vaccines to prevent Ebola virus disease. This may contribute to the future development of an Ebola vaccine.